Boston, MA –
June 12, 2025 — Receptor.AI, a leading AI-driven drug
discovery company, today announced the incorporation of the REAXENSETM
platform, developed by Reaxense Inc., a Canadian chemical and biotechnology
company specializing in custom synthesis services and supply of drug-like
molecules, into its multiplatform ecosystem.
REAXENSETM
integrates four chemical spaces, offered exclusively as part of the Receptor.AI
ecosystem: ● ChemoVista™ – A curated space of 8M+ in-stock
small molecules, optimized for hit discovery and lead optimization.
QC-validated and ready for high-throughput campaigns. ● VirtuSynthium™ – Navigate a space of 10¹⁶
synthesis-ready virtual compounds, built from over 1 million qualified reagents
and 1,000+ reaction rules, with real-time feasibility and rapid make-on-demand
synthesis. ● OmniPeptide Nexus™ – Design and optimize
peptides of 2 to 100 amino acids, including cyclic, stapled, or chemically
modified variants. Supports real-time 3D modeling, ADMET scoring, and
synthesis-ready output. ● MacroCyclePro™ – Create macrocyclic scaffolds
and peptidomimetics tailored for permeability and target engagement, ideal for
modulating protein–protein interactions or bRo5 space.
The seamless
incorporation of these platforms across Receptor.AI workflows has already
demonstrated improvements in synthesis flexibility and turnaround time in pilot
projects.
“While AI
accelerates compound design, the synthesis and experimental validation of
candidates remain critical,” said Yaroslav Bilokin, CEO of Reaxense Inc. “The
incorporation of REAXENSETM strengthens Receptor.AI’s
ability to deliver and synthesize lab-ready compounds with increased speed and
precision.”
“This incorporation
marks a major step toward building a full-stack, end-to-end drug discovery
infrastructure,” said Alan Nafiiev, CEO of Receptor.AI. “With REAXENSETM,
we move closer to bridging the gap between in silico prediction and real-world
therapeutic validation.”
Receptor.AI is a
preclinical TechBio company specializing in generative AI for drug discovery.
Receptor.AI has developed a robust, validated AI-driven ecosystem tailored to
address complex protein targets, comprising three core platforms: ● Small Molecule Platform: De novo AI-driven
design of small molecules by leveraging key interactions related to biological
activity with optimization of over 80 drug properties. ● Peptides Platform: AI-guided de novo design
and optimization of linear and cyclic peptides against challenging targets,
including “undruggable” protein-protein interactions. ● Induced Proximity Platform: Engineering
ternary complexes to transform structurally unresolved native and induced PPIs
into druggable targets. Built on extensive
experience and over 40 successful joint discovery projects, Receptor.AI’s
multiplatform ecosystem empowers researchers to design small molecules,
peptides, and induced proximity agents with unprecedented speed and accuracy.
By focusing on validated, modular workflows that integrate seamlessly into
existing R&D processes, Receptor.AI has become a trusted partner to big
pharma companies and academic institutions worldwide. For further information,
please visit the company’s website at receptor.ai. Reaxense Inc. is a
Canadian life sciences company headquartered in Ontario, focused on providing
advanced molecular design resources for pharmaceutical, biotechnology,
academic, and public-sector research. The company’s platform integrates curated
in-stock and virtual chemical libraries, AI-powered synthesis technologies, and
deep protein characterization across over 8,500 targets. Its suite of
tools—ChemoVista™, VirtuSynthium™, OmniPeptide Nexus™, MacroCyclePro™, and
RECEPTOR360™—enables structure-informed drug discovery at scale. Reaxense supports its
partners in developing data-driven, synthesis-ready compounds across a broad
range of therapeutic areas. For more information,
visit www.reaxense.com. ● Receptor.AI About Receptor.AI
About Reaxense Inc.
Press & Media Inquiries
Tetiana Skakun, Marketing Operations Specialist
tetiana.skakun@receptor.ai
